The WNT Inhibitor PRI-724 Depletes Endogenous SOX2 and Blocks SOX2 Upregulation by Therapeutic Regimes
5 affiliations
- 1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
- 2Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
- 3Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA
- 4Department of Pediatrics, Hematology and Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA
- 5Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA
Abstract
Background/Objectives: The stem cell transcription factor SOX2 is expressed in more than 20 types of cancer. SOX2 expression is also elevated by a wide range of clinically used drugs and has been linked causally to drug and radiation resistance. Hence, SOX2 is recognized as an important therapeutic target. This study set out to identify a small molecule inhibitor that reduces SOX2 in a wide range of tumor types. Methods: In this study, the WNT inhibitor, PRI-724 (Foscenvivint), was tested for its ability to downregulate SOX2 in ten tumor cell lines using western blot analysis. We also used western blot analysis to examine whether PRI-724 blocks the upregulation of SOX2 by clinically used drugs and radiation. Additionally, we examined the overall effects of PRI-724 on the transcriptome by performing RNA-Seq and STRING analysis. Results: PRI-724 not only downregulated SOX2 in ten different tumor cell lines representing eight different tumor types, but also blocked the upregulation of SOX2 induced by vemurafenib, gemcitabine and radiation. Besides downregulating SOX2 at the protein and RNA level, without altering the stability of SOX2 RNA, PRI-724 significantly modified the transcriptome. STRING analysis of the upregulated and downregulated genes indicates that PRI-724 altered the expression of genes involved in stress-response pathways, including endoplasmic reticulum (ER) stress. Conclusions: The WNT inhibitor PRI-724 downregulates SOX2 expression in a wide range of tumor cell types and blocks the upregulation of SOX2 by clinically used regimens. PRI-724 also modulates the expression of genes associated with stress-response pathways.
Related
- Combination of Radiation Treatment and PLK4-Inhibitor, CFI-400945, Leads to Upregulation of ICAM-1, STAT3 Activation, and Cellular Senescence in TNBC
- Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity
- 126 Discovery of endogenous retroviral antigens as candidate therapeutic targets in STAG2-mutant myeloid malignancies
- The Cutaneous Melatoninergic System: Endogenous Biology and Potential for Therapeutic Targeting
- Zileuton Beyond Asthma: A Multifaceted 5-Lipoxygenase Inhibitor With Emerging Therapeutic Potential Across Inflammation, Cancer, Neuroprotection, and Fibrosis
BibTeX
@article{sage2026inhibitor,
title = {{The WNT Inhibitor PRI-724 Depletes Endogenous SOX2 and Blocks SOX2 Upregulation by Therapeutic Regimes}},
author = {Alexander R. Sage and Daisy V. Gonzalez and Briana D. Ormsbee Golden and Ethan Metz and Rebecca E. Oberley-Deegan and Peter Xie and Donald W. Coulter and Chittalsinh Raulji and Grinu Mathew and Angie Rizzino},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213569},
url = {https://www.mdpi.com/2072-6694/18/21/3569},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The WNT Inhibitor PRI-724 Depletes Endogenous SOX2 and Blocks SOX2 Upregulation by Therapeutic Regimes
AU - Alexander R. Sage
AU - Daisy V. Gonzalez
AU - Briana D. Ormsbee Golden
AU - Ethan Metz
AU - Rebecca E. Oberley-Deegan
AU - Peter Xie
AU - Donald W. Coulter
AU - Chittalsinh Raulji
AU - Grinu Mathew
AU - Angie Rizzino
PY - 2026
DA - 2026/11/06
JO - Cancers
DO - 10.3390/cancers18213569
UR - https://www.mdpi.com/2072-6694/18/21/3569
AB - Background/Objectives: The stem cell transcription factor SOX2 is expressed in more than 20 types of cancer. SOX2 expression is also elevated by a wide range of clinically used drugs and has been linked causally to drug and radiation resistance. Hence, SOX2 is recognized as an important therapeutic target. This study set out to identify a small molecule inhibitor that reduces SOX2 in a wide range of tumor types. Methods: In this study, the WNT inhibitor, PRI-724 (Foscenvivint), was tested for its ability to downregulate SOX2 in ten tumor cell lines using western blot analysis. We also used western blot analysis to examine whether PRI-724 blocks the upregulation of SOX2 by clinically used drugs and radiation. Additionally, we examined the overall effects of PRI-724 on the transcriptome by performing RNA-Seq and STRING analysis. Results: PRI-724 not only downregulated SOX2 in ten different tumor cell lines representing eight different tumor types, but also blocked the upregulation of SOX2 induced by vemurafenib, gemcitabine and radiation. Besides downregulating SOX2 at the protein and RNA level, without altering the stability of SOX2 RNA, PRI-724 significantly modified the transcriptome. STRING analysis of the upregulated and downregulated genes indicates that PRI-724 altered the expression of genes involved in stress-response pathways, including endoplasmic reticulum (ER) stress. Conclusions: The WNT inhibitor PRI-724 downregulates SOX2 expression in a wide range of tumor cell types and blocks the upregulation of SOX2 by clinically used regimens. PRI-724 also modulates the expression of genes associated with stress-response pathways.
SN - 2072-6694
ER -